Clinical effects of prior trastuzumab on combination eribulin mesylate plus trastuzumab as first-line treatment for human epidermal growth factor receptor 2 positive locally recurrent or metastatic breast cancer: results from a Phase II, single-arm, multicenter study

Eribulin mesylate, a novel nontaxane microtubule dynamics inhibitor in the halichondrin class of antineoplastic drugs, is indicated for the treatment of patients with metastatic breast cancer who previously received ≥2 chemotherapy regimens in the metastatic setting. Primary data from a Phase II tri...

Descripción completa

Detalles Bibliográficos
Autores principales: Puhalla, Shannon, Wilks, Sharon, Brufsky, Adam M, O’Shaughnessy, Joyce, Schwartzberg, Lee S, Berrak, Erhan, Song, James, Vahdat, Linda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5153255/
https://www.ncbi.nlm.nih.gov/pubmed/27994483
http://dx.doi.org/10.2147/BCTT.S98696

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5153255/
https://www.ncbi.nlm.nih.gov/pubmed/27994483
http://dx.doi.org/10.2147/BCTT.S98696

Ejemplares similares